Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of the current study is to evaluate the efficacy and safety of \[177Lu\]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive (SSTR+), well differentiated Grade1 and Grade 2 (G1 and G2) (Ki-67 \<10%) advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with high disease burden
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rozległy lub przerzutowy nowotwór neuroendokrynny żołądkowo-jelitowo-trzustkowy, którego nie można operować
- •Nowotwór zdiagnozowany w ciągu ostatnich 6 miesięcy przed badaniem
- •Tumor lub przerzut większy niż 4 cm, lub wiele przerzutów większych niż 2 cm
- •Objawy choroby takie jak ból, zmęczenie, utrata wagi lub zaburzenia hormonalne
- •Wiek 12 lat lub więcej
- •Potwierdzenie receptorów dla pewnego hormonu na guzie (somatostatynowych) badaniem obrazowym
- •Prawidłowe funkcje szpiku kostnego i nerek przed rozpoczęciem leczenia
Simplified criteria — AI translation
Trial details
- Minimum age
- 12 Years
- Maximum age
- 100 Years
- Last updated (source)
- September 11, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (67)
Mayo Clinic Arizona
Scottsdale, United States
Highlands Oncology Group
Fayetteville, United States
Rocky Mountain Cancer Centers
Denver, United States
Hartford Hospital
Hartford, United States
Yale New Haven Hospital
New Haven, United States
Mayo Clinic Jacksonville
Jacksonville, United States
AdventHealth
Orlando, United States
Piedmont Healthcare
Atlanta, United States
Winship Cancer Institute
Atlanta, United States
St Elizabeth Healthcare
Edgewood, United States
LSU Medical Center
New Orleans, United States
Henry Ford Hospital
Detroit, United States
Mount Sinai Medical Center
New York, United States
Tennessee Oncology
Nashville, United States
TxO Austin Midtown
Austin, United States
Texas Oncology
Dallas, United States
Virginia Cancer Specialists
Fairfax, United States
Virginia Oncology Associates
Norfolk, United States
Blue Ridge Cancer Center
Wytheville, United States
Northwest Medical Specialties
Tacoma, United States
Novartis Investigative Site
Edmonton, Canada
Novartis Investigative Site
London, Canada
Novartis Investigative Site
Toronto, Canada
Novartis Investigative Site
Montreal, Canada
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Shanghai, China
Novartis Investigative Site
Bron, France
Novartis Investigative Site
Clichy, France
Novartis Investigative Site
Montpellier, France
Novartis Investigative Site
Nantes, France
Novartis Investigative Site
Pessac, France
Novartis Investigative Site
Toulouse, France
Novartis Investigative Site
Erlangen, Germany
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
München, Germany
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
Szeged, Hungary
Novartis Investigative Site
Cona, Italy
Novartis Investigative Site
Genova, Italy
Novartis Investigative Site
Milan, Italy
Novartis Investigative Site
Milan, Italy
Novartis Investigative Site
Rozzano, Italy
Novartis Investigative Site
Pisa, Italy
Novartis Investigative Site
Roma, Italy
Novartis Investigative Site
Roma, Italy
Novartis Investigative Site
Rotterdam, Netherlands
Novartis Investigative Site
Utrecht, Netherlands
Novartis Investigative Site
Gdansk, Poland
Novartis Investigative Site
Gliwice, Poland
Novartis Investigative Site
Krakow, Poland
Novartis Investigative Site
Poznan, Poland
Novartis Investigative Site
Warsaw, Poland
Novartis Investigative Site
Warsaw, Poland
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
L'Hospitalet de Llobregat, Spain
Novartis Investigative Site
Oviedo, Spain
Novartis Investigative Site
Barcelona, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Salamanca, Spain
Novartis Investigative Site
Glasgow, United Kingdom
Novartis Investigative Site
London, United Kingdom
Trial contact
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/12/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.